DBVTF DBV Technologies S.A.

NEUTRAL Impact: 2/10 8-K
Horizon months Filed Jun 5, 2026 Processed 9d 12h ago SEC 0001193125-26-259488
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

DBV Technologies granted CEO Daniel Tass 4,060,000 performance share units (PSUs) tied to FDA approval of Viaskin Peanut BLA(s) by July 1, 2028. The award is a routine compensatory arrangement with no immediate financial impact — no departure, no financial data, and no change to the company's operations or outlook.

Actionable Insight

This is a standard long-term incentive grant with no immediate trading signal. Monitor FDA catalyst timelines for Viaskin Peanut — the PSU structure aligns CEO incentives with regulatory success, but the filing itself does not change the company's risk profile or valuation.

Key Facts

  • CEO Daniel Tass received 4,060,000 PSUs under the newly approved 2026 Performance Share Unit Plan.
  • Vesting requires FDA approval of Viaskin Peanut BLA(s) by July 1, 2028, plus continued employment.
  • 2,900,000 PSUs vest on first FDA approval; 1,160,000 on second approval (or all if single BLA covers both age groups).
  • Vested shares deliver in four equal installments from July 2028 through January 2030.
  • No CEO departure, no financial results, no guidance, and no material agreement beyond the PSU grant.

Financial Impact

No financial figures reported; PSUs are contingent on future regulatory milestones with no current cash or earnings effect.

Risk Factors

  • PSUs expire worthless if FDA approvals are not achieved by July 1, 2028.
  • Potential dilution of ~4.06M ordinary shares upon vesting, though contingent on regulatory outcomes.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-259488
Document: 0001193125-26-259488-index-headers.html0001193125-26-259488
Document: 0001193125-26-259488-index.html0001193125-26-259488
Document: 0001193125-26-259488.txt0001193125-26-259488
2 reports for DBVTF
Performance horizon
Filters
Rows
Reports for DBVTF — sortable, filterable
Type Now
Jun 5, 2026
9d ago
8-K
NEUTRAL ★ 2/10
$4.26 awaiting T+20awaiting T+20$4.26 (+0.00%)
Apr 30, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$4.26 $4.26· 0.00%▼ −5.27%$4.26 (+0.00%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 5h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access